Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 5/2020

Open Access 26.06.2020 | Editorial

Impact of the metabolic syndrome on severe mental disorders

verfasst von: Andrea Schmitt, Daniela Reich-Erkelenz, Peter Falkai

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 5/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Compared to the general population, severe psychiatric disorders are associated with an increased mortality, which can largely be explained by a high incidence of somatic comorbidities, unhealthy lifestyle, low physical activity and increased rate of suicides [1]. For example, schizophrenia patients have a higher prevalence of the metabolic syndrome than the general population, with a two- to threefold increased risk for cardiovascular diseases (CVDs) resulting in increased cardiac mortality [2]. This leads to an estimated reduction in life expectancy of nearly 10–15 years compared to the general population. The metabolic syndrome is defined as a combination of increased waist circumference and two of the following criteria: high blood pressure, elevated triglycerides, low high-density lipoprotein (HDL) cholesterol and elevated fasting glucose, by the International Diabetes Federation. It is also defined by the Adult Treatment Panel III (ATP III) of the National Cholesterol Education and the adapted Adult Treatment Panel III (ATP III-A) of the American Heart Association, which require 3 criteria to be fulfilled [1].
The high prevalence of the metabolic syndrome has an impact on clinical outcome in patients with severe mental disorders. Using the IDF and ATP III criteria, 30.1% of psychiatric inpatients were found to be overweight, 17.2% obese and about 25% fulfilled criteria for metabolic syndrome. In fact, 3.8% had (pre)diabetes, 8.3% had a moderate and 1.9% a high CVD score [3]. In a follow-up study of schizophrenia patients, prevalence of the metabolic syndrome increased substantially after a mean of 8 years and the nutritional status was found to play a major role [4]. In patients with psychosis, high cholesterol and low-density lipoprotein (LDL) scores showed significant associations with depression [5]; while, an increase in HDL levels was related to improvement in verbal learning [6]. In trauma-exposed women, higher body mass index was associated with less cardiac output and heart rate recovery from a stress task, suggesting that PTSD recovery may be mediated by body mass index [7].
A position statement from the European Psychiatric Association (EPA) recommends the use of physical activity in routine clinical care of severe mental disorders such as schizophrenia and major depression to improve psychiatric and medical outcomes [8]. Aerobic exercise is affecting multiple organs and may positively influence neuroplastic processes as well as factors of the metabolic syndrome [9]. Therefore, current guidelines such as the German S3 Schizophrenia Guideline recommend its application in severe mental disorders. Further research is required on the neurobiological mechanisms by which aerobic exercise exerts its protective effects on factors of the metabolic syndrome and cognition. Furthermore, it should be investigated which mode and what duration of training are expected to have beneficial effects on cardiorespiratory fitness, metabolic parameters and symptoms of severe mental disorders [10].

Acknowledgments

Open Access funding provided by Projekt DEAL.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Neuer Inhalt

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Literatur
3.
6.
Zurück zum Zitat Gjerde PB, Simonsen CE, Lagerberg TV, Steen NE, Ueland T, Andreassen OA, Steen VM, Melle I (2020) Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum hdl levels in a cohort of first episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 270(1):49–58. https://doi.org/10.1007/s00406-019-01017-w CrossRefPubMed Gjerde PB, Simonsen CE, Lagerberg TV, Steen NE, Ueland T, Andreassen OA, Steen VM, Melle I (2020) Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum hdl levels in a cohort of first episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 270(1):49–58. https://​doi.​org/​10.​1007/​s00406-019-01017-w CrossRefPubMed
8.
Zurück zum Zitat Stubbs B, Vancampfort D, Hallgren M, Firth J, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll C, DeHert M, Gaughran F, Schneider F, Veronese N, Solmi M, Falkai P, Möller H-J, Kahl KG (2018) EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry 54:124–144CrossRef Stubbs B, Vancampfort D, Hallgren M, Firth J, Brand S, Cordes J, Malchow B, Gerber M, Schmitt A, Correll C, DeHert M, Gaughran F, Schneider F, Veronese N, Solmi M, Falkai P, Möller H-J, Kahl KG (2018) EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry 54:124–144CrossRef
9.
Zurück zum Zitat Maurus I, Hasan A, Röh A, Takahashi S, Rauchmann B, Keeser D, Malchow B, Schmitt A, Falkai P (2019) Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 269(5):499–515CrossRef Maurus I, Hasan A, Röh A, Takahashi S, Rauchmann B, Keeser D, Malchow B, Schmitt A, Falkai P (2019) Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 269(5):499–515CrossRef
10.
Zurück zum Zitat Schmitt A, Reich-Erkelenz D, Hasan A, Falkai P (2019) Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations. Eur Arch Psychiatry Clin Neurosci 269(5):483–484CrossRef Schmitt A, Reich-Erkelenz D, Hasan A, Falkai P (2019) Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations. Eur Arch Psychiatry Clin Neurosci 269(5):483–484CrossRef
Metadaten
Titel
Impact of the metabolic syndrome on severe mental disorders
verfasst von
Andrea Schmitt
Daniela Reich-Erkelenz
Peter Falkai
Publikationsdatum
26.06.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 5/2020
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-020-01156-5

Weitere Artikel der Ausgabe 5/2020

European Archives of Psychiatry and Clinical Neuroscience 5/2020 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.